---
title: "Adicet Bio wins FDA IND clearance for ADI-212 prostate cancer trial"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/297226436.md"
description: "Adicet Bio received FDA IND clearance for ADI-212 to treat metastatic castration-resistant prostate cancer. Phase 1 enrollment is expected to begin in Q4 2026."
datetime: "2026-08-27T20:00:22.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/297226436.md)
  - [en](https://longbridge.com/en/news/297226436.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/297226436.md)
generator: "portal-rs"
---

# Adicet Bio wins FDA IND clearance for ADI-212 prostate cancer trial

-   FDA cleared Adicet Bio’s IND for ADI-212 in metastatic castration-resistant prostate cancer. \* Phase 1 enrollment is expected to start in Q4 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adicet Bio Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202608271600BIZWIRE\_USPR\_\_\_\_\_20260827\_BW653039) on August 27, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [ACET.US](https://longbridge.com/en/quote/ACET.US.md)

## Related News & Research

- [Adicet Bio, Inc. (NASDAQ:ACET) Given Consensus Rating of "Moderate Buy" by Analysts](https://longbridge.com/en/news/296801308.md)
- [Adicet Bio Q2 FY26 net loss widens to $21.4 million; cash and short-term investments total $118.2 million](https://longbridge.com/en/news/295018537.md)
- [ADI Global Distribution Inc. Common Stock (NYSE:ADIG) Given Average Recommendation of "Hold" by Analysts](https://longbridge.com/en/news/297391529.md)
- [ADI Global Distribution to Participate in the Jefferies 2026 Industrials Conference | ADIG Stock News](https://longbridge.com/en/news/297163643.md)
- [Chemomab CEO Adi Mor presents at H.C. Wainwright Global Investor Conference](https://longbridge.com/en/news/297513939.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**